| Code | CSB-RA868352MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Procizumab, targeting dipeptidyl peptidase 3 (DPP3), a cytosolic metallopeptidase involved in the degradation of bioactive peptides. DPP3 plays a critical role in cardiovascular physiology by cleaving angiotensin II and other vasoactive peptides, thereby modulating blood pressure regulation and cardiac function. Elevated circulating DPP3 levels have been associated with acute circulatory failure, cardiogenic shock, and increased mortality in critically ill patients, making it an important biomarker and potential therapeutic target in cardiovascular medicine and critical care research.
Procizumab represents a novel therapeutic approach under clinical investigation for the treatment of cardiogenic shock and acute heart failure, functioning by neutralizing circulating DPP3 to restore hemodynamic stability. This biosimilar antibody provides researchers with a valuable tool for investigating DPP3-mediated pathways, exploring cardiovascular disease mechanisms, and conducting preclinical studies related to shock states and cardiac dysfunction. It enables the study of DPP3 biology and validation of therapeutic strategies targeting this emerging cardiovascular mediator.
There are currently no reviews for this product.